<DOC>
	<DOCNO>NCT00590278</DOCNO>
	<brief_summary>The pilot study design investigate value Neo-adjuvant Tomudez combination radiotherapy patient inoperable recurrent rectal cancer term response rate increase resectability initially inoperable rectal cancer .</brief_summary>
	<brief_title>A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable Recurrent Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>Confirmed diagnosis inoperable/recurrent rectal cancer Age &gt; 18 year At least 1 measurable lesion present WHO performance score &lt; 2 Life expentancy least 12 week Subjects consider appropriate receive systemic chemotherapy pelvic radiotherapy Documented inform consent participate trial Previous systemic chemotherapy Previous radiotherapy plan exposure area Subjects distant metastasis ( ) white blood cell &lt; 4.0x109/L ( unless absolute neutrophil count &gt; 2.0x109/L ( b ) Platelet count &lt; 100x109/L Serum creatinine upper limit normal range ( ) Serum bilirubin &gt; 1.25 time upper limit normal range ( b ) Asparate aminotransferase ( AST ) Alanine amiontransferase ( ALT ) &gt; 2.5 time upper limit normal range Any severe concurrent medical condition would make undesirable , clinician 's opinion , patient participate trial would jeopardise compliance trial period Pregnancy breast feeding . Women childbearing age must use effective contraception Previous current malignancy site , exception adequately treat insitu carcinoma cervix uteri basal squamous cell carcinoma skin Patient participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Tomudex</keyword>
	<keyword>inoperable rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>